THE UNIVERSITY OF NEW SOUTH WALES | UNSW SYDNEY NSW 2052 AUSTRALIAT +61(2) 9385 0000 | F +61 (2) 9385 0000 | ABN 57 195 873 179 | CRICOS Provider Code 00098G
SYDNEY | CANBERRA | AUSTRALIA
12 August 2013
UNSW response to questions raised concerning research into thecompound DZ13
The ABC has raised concerns regarding DZ13, a compound that aims totarget tumour growth. The work on DZ13 is a collaborative effort involvinga number of researchers. A clinical trial, sponsored by UNSW and funded by the Cancer InstituteNSW, commenced in 2010. The trial involved nine patients with skincancer and was conducted at Sydney’s Royal Prince Alfred Hospital.This first phase of the trial tested toxicology and tolerability. It wascompleted successfully and the results were published in
The Lancet, Vol 381, May 25, 2013, pages 1835 -1843
.The next stage of the clinical trial, which was due to test the effectivenessof DZ13, was suspended by UNSW in July 2013 due to concernsregarding aspects of the science underpinning DZ13. The trial had yet tocommence patient recruitment.Patient safety is the University’s top priority. The decision was made toerr on the side of caution until concerns regarding some of the scienceunderpinning DZ13 have been resolved. It should be stressed that theseconcerns do not relate to either the conduct of the trial or to the safety of the DZ13 compound.The ABC has put a number of questions to the University regardingconcerns raised about DZ13.In 2009/2010 the University was made aware of possible issuesregarding a draft manuscript related to DZ13. The University takes anyconcerns regarding the conduct of research very seriously. Theseconcerns were investigated by an independent external panel of experts.There were no findings of research misconduct. As part of their investigation, the independent experts were specificallyasked to advise whether the matters being investigated gave rise to anyconcerns about the clinical trial that was underway. The Panel advisedthe University that the matters under investigation were not relevant tothe clinical trial.